Back to Blog
Fragment 15/7/2023 ![]() ![]() There was no significant association between D-dimer elevation and thrombosis on multivariable analysis.Overall, PF1.2 and D-dimer were moderately positively correlated (r = 0.542, P 523 pmol/L For further analyses, 37 patients who were on therapeutic anticoagulation were excluded. Over the median follow-up of 29 hospital days, 56 patients (49%) developed VTE or a non-vessel thrombotic manifestation. In addition to venous thromboembolism (VTE), clinically significant non-vessel thrombotic manifestations were evaluated (clotting of a line or hemofiltration circuit). Analyses comparing PF1.2 and D-dimer compared values measured on the same day, usually in the same blood draw. The study involved 115 patients hospitalized with COVID-19 at Mass General who had PF1.2 measured at any time during their hospitalization between April 1 and May 6, 2020. Their findings appear in the American Journal of Hematology. Now, expanding on those previous findings, Hanny Al-Samkari, MD, a classical hematologist and clinical investigator, at the Center for Hematology at the Mass General Cancer Center, and Rachel Rosovsky, MD, of the Center for Hematology at the Mass General Cancer Center, and colleagues report that prothrombin fragment 1.2 (PF1.2) was more discriminant than D-dimer in identifying thrombosis in hospitalized patients with COVID-19. Researchers at Massachusetts General Hospital have reported that D-dimer elevation at admission predicts bleeding, thrombosis, critical illness and death in patients with COVID-19. Numerous studies have reported hypercoagulability in critically ill patients with COVID-19, and this complication can be fatal or lead to considerable morbidity. ![]() ![]() Error: Please enter a valid email address. ![]()
0 Comments
Read More
Leave a Reply. |